Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946912773> ?p ?o ?g. }
- W2946912773 endingPage "510" @default.
- W2946912773 startingPage "510" @default.
- W2946912773 abstract "510 Background: In TNBC, the interplay between immunophenotype, tumor proliferation (prolif) and achievement of pathologic complete response (pCR) with neoadjuvant chemotherapy (NAC) remains unknown. Methods: RNA seq was performed on pre-tx research biopsies of stage II/III TNBC enrolled in BrighTNess. NAC regimens included paclitaxel alone or with carboplatin (Cb) or Cb plus veliparib, followed by AC. Computational analysis included subtyping (i.e. PAM50, Pietenpol), prolif (PAM50) and GeparSixto immune signature (GSIS). Cb-containing arms were combined due to similar pCR. Results: High quality RNA seq data was obtained from 482 of 634 pts. PAM50 classified 80.1% of tumors as basal-like. TNBC subtypes were mostly BL1 or BL2 (23.3%), IM (22.4%) or M/MSL (31.7%); 6% were LAR. pCR was higher for basal vs non-basal tumors (52.3% vs 35.4%, p = 0.003). IM had the highest pCR rate (64.2%, 95% CI 59.9%,68.5%). Basal-like was not a significant predictor for Cb benefit (p-interaction = 0.8). Prolif (OR = 0.30 p < 0.001) and GSIS (OR 0.68 p < 0.001) were significantly correlated with pCR but did not correlate with each other (Pearson’s r2 = 0.027). In multivariate analysis, prolif (HR = 0.36 95% CI, 0.21-0.61 p = 0.0002) and GSIS (HR = 0.62 95% CI, 0.49-0.79 p < 0.0001) increased the ability to predict pCR beyond standard clinico-pathologic variables (likelihood ratio = 14.9, p = 0.0001115). Among all pts, those above the median for both prolif. and GSIS had the highest pCR (67%; 84/125) while those below the median for both had the lowest pCR rate (34%; 42/125). Tumors with higher inferred CD8 + T-cell infiltration demonstrated greater benefit from Cb using either TIMER (HR = 0.83 [0.73-0.95]) or CIBERSORT (HR = 0.83 [0.76-0.91]). Tumors with higher inferred total macrophages, particularly immune suppressive M2 macrophages had a higher pCR rate on the non-Cb arm (AC-T) using CIBERSORT (HR = 1.27 [1.07,1.50]). Conclusions: Immunophenotype and proliferation are independent predictors of pCR to standard NAC regimens in TNBC. PAM50 is not a significant predictor of Cb benefit. Exploratory findings suggest that tumor infiltrating immunophenotype (i.e. CD8 T cells and macrophages) may predict response to specific NAC regimens in TNBC. Clinical trial information: NCT02032277." @default.
- W2946912773 created "2019-06-07" @default.
- W2946912773 creator A5001315712 @default.
- W2946912773 creator A5002068827 @default.
- W2946912773 creator A5003405177 @default.
- W2946912773 creator A5007830810 @default.
- W2946912773 creator A5011410319 @default.
- W2946912773 creator A5016516852 @default.
- W2946912773 creator A5026132340 @default.
- W2946912773 creator A5033578335 @default.
- W2946912773 creator A5033698551 @default.
- W2946912773 creator A5041912334 @default.
- W2946912773 creator A5045617170 @default.
- W2946912773 creator A5049785882 @default.
- W2946912773 creator A5055013606 @default.
- W2946912773 creator A5059093147 @default.
- W2946912773 creator A5063504632 @default.
- W2946912773 creator A5067146231 @default.
- W2946912773 creator A5087559224 @default.
- W2946912773 creator A5089519845 @default.
- W2946912773 creator A5090188675 @default.
- W2946912773 date "2019-05-20" @default.
- W2946912773 modified "2023-10-02" @default.
- W2946912773 title "Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study." @default.
- W2946912773 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.510" @default.
- W2946912773 hasPublicationYear "2019" @default.
- W2946912773 type Work @default.
- W2946912773 sameAs 2946912773 @default.
- W2946912773 citedByCount "5" @default.
- W2946912773 countsByYear W29469127732020 @default.
- W2946912773 countsByYear W29469127732021 @default.
- W2946912773 countsByYear W29469127732022 @default.
- W2946912773 crossrefType "journal-article" @default.
- W2946912773 hasAuthorship W2946912773A5001315712 @default.
- W2946912773 hasAuthorship W2946912773A5002068827 @default.
- W2946912773 hasAuthorship W2946912773A5003405177 @default.
- W2946912773 hasAuthorship W2946912773A5007830810 @default.
- W2946912773 hasAuthorship W2946912773A5011410319 @default.
- W2946912773 hasAuthorship W2946912773A5016516852 @default.
- W2946912773 hasAuthorship W2946912773A5026132340 @default.
- W2946912773 hasAuthorship W2946912773A5033578335 @default.
- W2946912773 hasAuthorship W2946912773A5033698551 @default.
- W2946912773 hasAuthorship W2946912773A5041912334 @default.
- W2946912773 hasAuthorship W2946912773A5045617170 @default.
- W2946912773 hasAuthorship W2946912773A5049785882 @default.
- W2946912773 hasAuthorship W2946912773A5055013606 @default.
- W2946912773 hasAuthorship W2946912773A5059093147 @default.
- W2946912773 hasAuthorship W2946912773A5063504632 @default.
- W2946912773 hasAuthorship W2946912773A5067146231 @default.
- W2946912773 hasAuthorship W2946912773A5087559224 @default.
- W2946912773 hasAuthorship W2946912773A5089519845 @default.
- W2946912773 hasAuthorship W2946912773A5090188675 @default.
- W2946912773 hasConcept C121608353 @default.
- W2946912773 hasConcept C126322002 @default.
- W2946912773 hasConcept C143998085 @default.
- W2946912773 hasConcept C196166836 @default.
- W2946912773 hasConcept C203014093 @default.
- W2946912773 hasConcept C2776694085 @default.
- W2946912773 hasConcept C2778292576 @default.
- W2946912773 hasConcept C530470458 @default.
- W2946912773 hasConcept C553184892 @default.
- W2946912773 hasConcept C71924100 @default.
- W2946912773 hasConceptScore W2946912773C121608353 @default.
- W2946912773 hasConceptScore W2946912773C126322002 @default.
- W2946912773 hasConceptScore W2946912773C143998085 @default.
- W2946912773 hasConceptScore W2946912773C196166836 @default.
- W2946912773 hasConceptScore W2946912773C203014093 @default.
- W2946912773 hasConceptScore W2946912773C2776694085 @default.
- W2946912773 hasConceptScore W2946912773C2778292576 @default.
- W2946912773 hasConceptScore W2946912773C530470458 @default.
- W2946912773 hasConceptScore W2946912773C553184892 @default.
- W2946912773 hasConceptScore W2946912773C71924100 @default.
- W2946912773 hasIssue "15_suppl" @default.
- W2946912773 hasLocation W29469127731 @default.
- W2946912773 hasOpenAccess W2946912773 @default.
- W2946912773 hasPrimaryLocation W29469127731 @default.
- W2946912773 hasRelatedWork W2129067399 @default.
- W2946912773 hasRelatedWork W2150100001 @default.
- W2946912773 hasRelatedWork W2354425668 @default.
- W2946912773 hasRelatedWork W2371925745 @default.
- W2946912773 hasRelatedWork W2560572982 @default.
- W2946912773 hasRelatedWork W2588271732 @default.
- W2946912773 hasRelatedWork W2602518406 @default.
- W2946912773 hasRelatedWork W2604493577 @default.
- W2946912773 hasRelatedWork W2762099239 @default.
- W2946912773 hasRelatedWork W2805124128 @default.
- W2946912773 hasRelatedWork W2805197306 @default.
- W2946912773 hasRelatedWork W2890267191 @default.
- W2946912773 hasRelatedWork W2897993531 @default.
- W2946912773 hasRelatedWork W2954677012 @default.
- W2946912773 hasRelatedWork W2995903922 @default.
- W2946912773 hasRelatedWork W3014196977 @default.
- W2946912773 hasRelatedWork W3031073972 @default.
- W2946912773 hasRelatedWork W3032718513 @default.
- W2946912773 hasRelatedWork W3111065894 @default.
- W2946912773 hasRelatedWork W3155211385 @default.
- W2946912773 hasVolume "37" @default.
- W2946912773 isParatext "false" @default.